{
    "id": "a6d48e99-4411-4724-8372-b01692a5dff7",
    "indications": {
        "text": "ambrisentan tablets indicated treatment pulmonary arterial hypertension ( pah ) ( group 1 ) adult patients : improve exercise ability delay worsening . establishing effectiveness included predominantly patients functional class ii iii symptoms etiologies idiopathic heritable pah ( 60 % ) pah associated connective tissue diseases ( 34 % ) .",
        "doid_entities": [
            {
                "text": "hypertension (DOID:10763)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_10763"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "\u2022 initiate treatment 5 mg daily ( 2.1 ) . \u2022 titrate 4-week intervals needed tolerated ( 2.1 ) . \u2022 split , crush , chew tablets ( 2.1 ) .",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "ambrisentan tablets 5 mg pale pink , film-coated , square shaped convex tablets debossed \u201c \u201d one side \u201c 5 \u201d side supplied follows : bottles 30 ndc 59651-494-30 ambrisentan tablets 10 mg deep pink , film-coated , oval shaped convex tablets debossed \u201c \u201d one side \u201c 10 \u201d side supplied follows : bottles 30 ndc 59651-495-30 store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) ; excursions permitted 15\u00b0 30\u00b0c ( 59\u00b0 86\u00b0f ) [ usp controlled room temperature ] . store ambrisentan tablets original packaging .",
    "adverseReactions": "pregnancy ( 4.1 ) idiopathic pulmonary fibrosis ( 4.2 )",
    "ingredients": [
        {
            "name": "AMBRISENTAN",
            "code": "HW6NV07QEC",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_135949"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14158"
        },
        {
            "name": "FD&C RED NO. 40",
            "code": "WZB9127XOA"
        },
        {
            "name": "LECITHIN, SOYBEAN",
            "code": "1DI56QDM62",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_61995"
        },
        {
            "name": "POLYETHYLENE GLYCOL 3350",
            "code": "G2M7P15E5P",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_13643"
        },
        {
            "name": "POLYVINYL ALCOHOL, UNSPECIFIED",
            "code": "532B59J990",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30879"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32178"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        }
    ],
    "organization": "Aurobindo Pharma Limited",
    "name": "ambrisentan",
    "effectiveTime": "20250421",
    "indications_original": "Ambrisentan tablets are indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in adult patients:\n                  \n                  \n                     To improve exercise ability and delay clinical worsening.\n                  \n                  Studies establishing effectiveness included predominantly patients with WHO Functional Class II to III symptoms and etiologies of idiopathic or heritable PAH (60%) or PAH associated with connective tissue diseases (34%).",
    "contraindications_original": "\u2022 Initiate treatment at 5 mg once daily ( 2.1 ). \u2022 Titrate at 4-week intervals as needed and tolerated ( 2.1 ). \u2022 Do not split, crush, or chew tablets ( 2.1 ).",
    "warningsAndPrecautions_original": "Ambrisentan Tablets 5 mg are pale pink, film-coated, square shaped convex tablets debossed with \u201cAS\u201d on one side and \u201c5\u201d on other side and are supplied as follows:\n                  \n                  Bottles of 30\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC\u00a0\u00a0 59651-494-30\n                  \n                  \n                     Ambrisentan Tablets 10 mg are deep pink, film-coated, oval shaped convex tablets debossed with \u201cAS\u201d on one side and \u201c10\u201d on other side and are supplied as follows:\n                  \n                  Bottles of 30\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 NDC\u00a0\u00a0 59651-495-30\n                  \n                  Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F); excursions permitted to 15\u00b0 to 30\u00b0C (59\u00b0 to 86\u00b0F) [See USP Controlled Room Temperature]. Store ambrisentan tablets in its original packaging.",
    "adverseReactions_original": "Pregnancy ( 4.1 ) Idiopathic Pulmonary Fibrosis ( 4.2 )",
    "drug": [
        {
            "name": "ambrisentan",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_135949"
        }
    ]
}